(Q44842467)

6 December 2017

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease (English)

1 reference

6 December 2017

1 reference

8

1 reference

6 December 2017

Guy Van Camp

1

1 reference

6 December 2017

Anja Flamez

2

1 reference

6 December 2017

Bernard Cosyns

3

1 reference

6 December 2017

Caroline Weytjens

4

1 reference

6 December 2017

Luc Muyldermans

5

1 reference

6 December 2017

Michel Van Zandijcke

6

1 reference

6 December 2017

Johan De Sutter

7

1 reference

6 December 2017

Pierre Decoodt

9

1 reference

6 December 2017

Christian Moerman

10

1 reference

6 December 2017

Danny Schoors

11

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

6 December 2017

1 reference

6 December 2017

363

1 reference

6 December 2017

9416

1 reference

6 December 2017

1179-1183

1 reference

Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide

6 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

Pleuropulmonary disease due to pergolide use for restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

Valvular heart disease in patients taking pergolide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

Determinants of exercise-induced changes in mitral regurgitation in patients with coronary artery disease and left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915945-X

7 January 2021

10.1016/S0140-6736(04)15945-X

Identifiers

DOI

1 reference

6 December 2017

1 reference